Category — Healthcare
The National Health Systems Resource Center (NHSRC) under India’s Ministry of Health and Family Welfare, Government of India, has been appointed as the World Health Organization’s Collaborating Center for Priority Medical Devices and Health Technology, the first such center in South East Asia, says a news item from GroundReport.
On the occasion, the health secretary B.P. Sharma stated, “Prioritizing medical devices and health technology in the country is an important agenda item. It is critical to have the specifications in place for the medical devices and equipment that are already procured and used in the system. There is also need for dedicated medical devices testing laboratories to ensure the safety and efficacy of these devices.”
Dr. Nata Menabde, the WHO representative for India, commented, “There is a need for appropriate and applicable health care technology in India. Our medical devices industry is under-invested and heavily import driven at present, but with the current “Make in India” campaign, there is a huge opportunity for growth and expansion of the medical device industry. This would highly improve the access of essential medical devices and healthcare technology to patients in India.”
The division of Healthcare Technology & Innovation at NHSRC has been working in the area of health technologies and related policy interfaces. The scope of its work includes:
- Framing technical specifications for technologies procured under the National Health Mission
- Collating information on best practices for technology life cycle management and maintenance
- Creating a secretariat for the assessment and uptake of innovations into public health systems
- Proposing a road map for establishing testing laboratories
- Supporting the Health Ministry on issues related to free essential diagnostics and other technology intensive services
- Enhancing domestic manufacturing capacity
- Monitoring quality and safety criteria for healthcare technologies
- Conducting health technology assessments
March 30, 2015 No Comments
India is a $3.1 billion market for medical devices and the government will soon institute a Materio Vigilance Program of India (MvPI) to enable a systematic collection of data on the use of these devices. This data will form the basis for regulatory decisions and recommendations on their safe usage.
The program will be coordinated by the Indian Pharmacopoeia Commission, and envisages district hospitals, medical colleges and corporate hospitals. The biotechnology wing of the prestigious Sree Chitra Thirunal Institute of Medical Sciences and Technology in Thiruvananthapuram, Kerala will be the national collaborating center for the program which will run in collaboration with the Central Drug Standard Control Organization. Technical support for the program will be provided by the Division of Healthcare Technology, a proposed WHO collaborating center for priority medical devices and health technology policy in the National Health Systems Resources Center.
The MvPI program is meant to:
- monitor medical device associated adverse events (MDAE)
- create awareness among health care professionals about the importance of MDAE reporting in India,
- monitor the benefit-risk profile of medical devices
- generate independent, evidence-based recommendations on the safety of medical devices
- communicate the findings to all key stakeholders
March 17, 2015 No Comments
Advet Bhambhani Ventures (ABV), a Dubai-based healthcare service provider, plans to establish India first “luxury” hospital chain. Live Mint reports that Advet Bhambhani, CEO of the ABV Group said, “ABV is looking at an investment of at least $64 million for facilities at multiple locations in the country and will have its first hospital in Mumbai.”
There is a demand for luxury hospitals in the country that will provide superior quality of services and treatment among the rich and the ultra-rich who otherwise prefer to go Singapore or U.S., and to address this requirement ABV will set up all-suite hospitals in India’s metros and some other cities. India’s private healthcare market is dominated by corporate hospital chains such as Apollo Hospitals, Fortis Healthcare, Max Healthcare Ltd., and Wockhardt Hospitals Ltd., which have been raising their market share. Two non-resident Indian groups —Dubai-based Aster DM Healthcare Llc., and Abu Dhabi-based NMC Healthcare have already established a presence in the country.
March 3, 2015 No Comments
Mylan Pharmaceuticals Private Limited, the Indian subsidiary of Mylan Inc., has entered into an agreement with Gilead Sciences, under which it has been appointed the exclusive distributor of Sovaldi® (sofosbuvir 400mg tablets) and Harvoni®(ledipasvir 90mg/sofosbuvir 400 mg tablets) for the treatment of chronic hepatitis C, in India. Mylan expects to begin distribution of Sovaldi in India in Q2 2015. Sovaldi received regulatory approval in India in January 2015 – the first country in Asia to approve the medicine.
Mylan President Rajiv Malik said that Hepatitis C was a growing public health concern, and Mylan was proud to partner with Gilead for life-saving medications for the 12 million hepatitis C patients in India.
February 25, 2015 No Comments
According to a PricewaterhouseCoopers report quoted in Outlook Magazine, the Indian healthcare delivery system has limited resources and will need an investment of $245 billion to deliver desired outcomes in the next two decades. India needs 3.5 million new hospital beds, 3 million doctors and 6 million nurses over a period of 20 years, it added.
Other than the mentioned physical infrastructure, poor health outcomes such as low life expectancy, high infant and maternal mortality rates will also need to be addressed:
- India must increase life expectancy at birth from 66 years in 2012 to 71 years by 2024 and to 80 years by 2034.
- Infant mortality rate (number of infant deaths per 1000 live births), needs to decrease from 44 to 31 in 2024 and to 12 in 2034.
- Maternal mortality rate (number of maternal deaths per 100,000 live births), which is at 190 today, could decrease to 124 in 2024 to 27 in 2034.
To achieve these targets, healthcare providers must focus on improving the reach, quality, and affordability of healthcare exhorts the report. It further suggests that India can leverage its strength as a world leader in vaccine manufacturing ─ it contributes 60% of global production − to sharpen its focus on preventive care.
January 28, 2015 No Comments